Nurses' guide to understanding and implementing the National Comprehensive Cancer Network guidelines for myeloid growth factors

Oncology Nursing Forum

Volumn 34, Issue 2, 2007, Pages 347-353

  Wilson, Barbara J ^a   Gardner, Allison E ^b  

^a UNIVERSITY OF MARY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR;

ADULT; AGED; CHEMICALLY INDUCED DISORDER; CONSENSUS; EVIDENCE BASED MEDICINE; HUMAN; METHODOLOGY; NEOPLASM; NEUTROPENIA; NURSING; ONCOLOGY NURSING; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; STANDARD; UNITED STATES;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COLONY-STIMULATING FACTORS; CONSENSUS; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASMS; NEUTROPENIA; ONCOLOGIC NURSING; PRACTICE GUIDELINES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 34548412094     PISSN: 0190535X     EISSN: 15380688     Source Type: Journal    
DOI: 10.1188/07.ONF.347-353     Document Type: Review

References (27)

1. Ardizzoni, A., Favaretto, A., Boni, L., Baldini, E., Castiglioni, F., Antonelli, P., et al. (2005). Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: Results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis - A Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study. Journal of Clinical Oncology, 23, 569-575.
2. Balducci, L., & Repetto, L. (2004). Increased risk of myelotoxicity in elderly patients with non-Hodgkin lymphoma. Cancer, 100, 6-11.
3. Berlex. (2006). Leukine® [Prescribing information]. Seattle, WA: Author.
4. Budman, D.R., Berry, D.A., Cirrincione, C.T., Henderson, I.C., Wood, W.C., Weiss, R.B., et al. (1998). Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia group B. Journal of the National Cancer Institute, 90, 1205-1211.
5. Crawford, J., Dale, D., Wolff, D., Culakova, E., Poniewierski, M., Lyman, G., et al. (2005, June). Risk of neutropenic events during the first cycle of systemic cancer chemotherapy: Results from a prospective study [Abstract 06-049]. Presented at the 17th Multinational Association for Supportive Care in Cancer/International Society for Oral Oncology International Symposium, Geneva, Switzerland.
6. Donohue, R.B. (2006). Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia. Oncology Nursing Forum, 33, 347-352.
7. Houston, D. (1997). Supportive therapies for cancer chemotherapy patients and the role of the oncology nurse. Cancer Nursing, 20, 409-413.
8. Kuderer, N.M., Crawford, J., Dale, D., & Lyman, G.H. (2005). Meta-analysis of prophylactic granulocyte colony-stimulating (G-CSF) factor in cancer patients receiving chemotherapy [Abstract 8117]. Proceedings of the American Society of Clinical Oncology, 23, 758s.
9. Kwak, L.W., Halpern, J., Olshen, R.A., & Horning, S.J. (1990). Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. Journal of Clinical Oncology, 8, 963-977.
10. Lyman, G.H. (2005). Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: A review of the evidence. Journal of the National Comprehensive Cancer Network, 3, 557-571.
11. Lyman, G.H., Crawford, J., Wolff, D., Culakova, E., Poniewierski, M.S., Dale, D.C., et al. (2005). A risk model for first cycle febrile neutropenia in cancer patients receiving systemic chemotherapy [Abstract 8122]. Proceedings of the American Society of Clinical Oncology, 23, 759s.
12. Lyman, G.H., Dale, D.C., & Crawford, J. (2003). Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. Journal of Clinical Oncology, 21, 4524-4531.
13. Lyman, G.H., Dale, D.C., Friedberg, J., Crawford, J., & Fisher, R.I. (2004). Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: A nationwide study. Journal of Clinical Oncology, 22, 4302-4311.
14. Lyman, G.H., Lyman, C.H., & Agboola, O. (2005). Risk models for predicting chemotherapy-induced neutropenia. Oncologist, 10, 427-437.
15. Lyman, G.H., Morrison, V.A., Dale, D.C., Crawford, J., Delgado, D.J., Fridman, M., et al. (2003). Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leukemia and Lymphoma, 44, 2069-2076.
16. Maxon, J. (2005). Chemotherapy-induced neutropenia and the AIM Higher initiative: A report from the 2005 Congress of the Oncology Nursing Society. Retrieved January 20, 2006, from http://www.professional.cancerconsultants.com/ conferencecoverage.aspx?id=34729
17. Maxwell, C., Winkler, L., & Lottenburg, M. (2002, April). Nurse driven neutropenia management guidelines: Improving patient outcomes through evidence-based practice [Abstract 171]. Presented at the Oncology Nursing Society 27th Annual Congress, Washington, DC.
18. Michelson, J.L., Bergen, S., Cichetti, E., Doherty, E., Emens, C., & Parrone, M.K. (2002, April). Using a neutropenia management protocol to achieve dose intensity for optimal clinical outcome of chemotherapy [Abstract 169]. Presented at the Oncology Nursing Society 27th Annual Congress, Washington, DC.
19. Morrison, V.A., Picozzi, V., Scott, S., Pohlman, B., Dickman, E., Lee, M., et al. (2001). The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: A risk factor analysis. Clinical Lymphoma, 2, 47-56.
20. National Comprehensive Cancer Network. (2006). Clinical practice guidelines: Myeloid growth factors in cancer treatment. Retrieved January 20, 2006, from http://www.nccn.org/professionals/physician_gls/PDF/myeloid_growth. pdf
21. Picozzi, V.J., Pohlman, B.L., Morrison, V.A., Lawless, G.D., Lee, M.W., Kerr, R.O., et al. (2001). Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma. Oncology, 15, 1296-1306.
22. Repetto, L., Biganzoli, L., Koehne, C.H., Luebbe, A.S., Soubeyran, P., TjanHeijnen, V.C., et al. (2003). EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. European Journal of Cancer, 39, 2264-2272.
23. Ropka, M.E., Padilla, G., & Gillespie, T.W. (2005). Risk modeling: Applying evidence-based risk assessment in oncology nursing practice. Oncology Nursing Forum, 32, 49-56.
24. Smith, T.J., Khatcheressian, J., Lyman, G.H., Ozer, H., Armitage, J.O., Balducci, L., et al. (2006). 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. Journal of Clinical Oncology, 24, 3187-3205.
25. Vogel, C.L., Wojtukiewicz, M.Z., Carroll, R.R., Tjulandin, S.A., Barajas-Figueroa, L.J., Wiens, B.L., et al. (2005). First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study. Journal of Clinical Oncology, 23, 1178-1184.
26. White, N., & Keehne-Miron, J. (2002, April). Assessing clinical outcomes in breast cancer patients in a community-based cancer center [Abstract 102]. Presented at the Oncology Nursing Society Congress 27th Annual, Washington, DC.
27. White, N., Maxwell, C., Michelson, J., & Bedell, C. (2005). Protocols for managing chemotherapy-induced neutropenia in clinical oncology practices. Cancer Nursing, 28, 62-69.